Foghorn therapeutics provides third quarter 2024 financial and corporate update

First patient dosed with first-in-class smarca2(brm) selective inhibitor fhd-909 (ly4050784) in phase 1 trial with primary target population in smarca4(brg1) mutated nsclc

FHTX Ratings Summary

FHTX Quant Ranking